Noah Medical’s bronchoscopy robot has had its first use at a Hong Kong hospital, kicking off the company’s first clinical trial in Asia. The US-based company announced that the first patients have been enrolled in a trial to test the Galaxy System. A successful first procedure was carried out at the Prince of Wales Hospital in Hong Kong, marking a potential entry into the Asian market for the device that previously received US Food and Drug Administration (FDA) clearance in May of this year. The Galaxy System marks Noah Medical’s first commercial robotic device and entry into the rapidly growing healthcare robotics market. Noah Medical said that in a previous US-based clinical trial of the system earlier this year, the system was able to achieve a completely successful navigation to and targeting of a pulmonary legion in 100% of cases. Following 18 patients over the course of six months following surgery, the trial also found the device to have an 89.5% to 94.7% diagnostic yield.